Lønning PE - Search Results

1

Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.

Busch C, Geisler J, Knappskog S, Lillehaug JR, Lønning PE. Busch C, et al. Among authors: lonning pe. J Invest Dermatol. 2010 Oct;130(10):2514-6. doi: 10.1038/jid.2010.138. Epub 2010 May 27. J Invest Dermatol. 2010. PMID: 20505745 Free article. No abstract available.

2

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G. Lauss M, et al. Among authors: lonning pe. J Invest Dermatol. 2015 Jul;135(7):1820-1828. doi: 10.1038/jid.2015.61. Epub 2015 Feb 23. J Invest Dermatol. 2015. PMID: 25705847 Free PMC article.

3

Chemosensitivity and p53; new tricks by an old dog.

Lønning PE, Knappskog S. Lønning PE, et al. Breast Cancer Res. 2012 Nov 6;14(6):325. doi: 10.1186/bcr3326. Breast Cancer Res. 2012. PMID: 23131146 Free PMC article.

4

A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.

Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE. Knappskog S, et al. Among authors: lonning pe. Genes Chromosomes Cancer. 2006 Dec;45(12):1155-63. doi: 10.1002/gcc.20379. Genes Chromosomes Cancer. 2006. PMID: 17001621

5

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Knappskog S, Lønning PE. Knappskog S, et al. Among authors: lonning pe. Transcription. 2011 Sep-Oct;2(5):207-10. doi: 10.4161/trns.2.5.16813. Transcription. 2011. PMID: 22231115 Free PMC article. Review.

6

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S. Berge EO, et al. Among authors: lonning pe. Biochim Biophys Acta. 2013 Mar;1830(3):2790-7. doi: 10.1016/j.bbagen.2012.12.004. Biochim Biophys Acta. 2013. PMID: 23246812

7

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J. Tahiri A, et al. Among authors: lonning pe. PLoS One. 2013 Aug 30;8(8):e72692. doi: 10.1371/journal.pone.0072692. eCollection 2013. PLoS One. 2013. PMID: 24023633 Free PMC article.

8

Aromatase inhibitors--socio-economical issues.

Lønning PE, Geisler J. Lønning PE, et al. J Steroid Biochem Mol Biol. 2005 May;95(1-5):137-42. doi: 10.1016/j.jsbmb.2005.04.006. J Steroid Biochem Mol Biol. 2005. PMID: 15955693

9

Impact of aromatase inhibitors on bone health in breast cancer patients.

Geisler J, Lønning PE. Geisler J, et al. Among authors: lonning pe. J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):294-9. doi: 10.1016/j.jsbmb.2009.10.004. Epub 2009 Oct 13. J Steroid Biochem Mol Biol. 2010. PMID: 19833206

10

Aromatase inhibitors--socioeconomical issues.

Lønning PE, Geisler J. Lønning PE, et al. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):55-61. doi: 10.1016/j.jsbmb.2007.05.002. Epub 2007 May 24. J Steroid Biochem Mol Biol. 2007. PMID: 17604616

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

380 results

Search Page